目的 观察脂联素及其受体在钙化大鼠血管组织中的变化,探讨脂联素(adiponectin, APN)对钙化组织的作用。方法 大鼠随机分为正常对照组、钙化组和脂联素组。制备大鼠血管钙化模型。用ELISA法测定血浆和血管组织中脂联素的含量,用real-time PCR方法检测组织中脂联素与其受体adipo R1的mRNA水平,用Western blot方法检测组织中受体adipo R1蛋白含量,测定血管中钙含量及碱性磷酸酶活性。结果 与对照组相比,钙化大鼠血浆和血管组织中脂联素的含量明显降低,分别降低了47.1% 和 57.1%;钙化组大鼠血管组织中APN 和adipo R1 mRNA 水平较对照组有显著降低,分别降低了65.0 %和72.0 %;钙化大鼠的血管组织中adipo R1蛋白降低了77.2%(均P<0.01)。给予脂联素的大鼠血管组织中钙含量和碱性磷酸酶活性分别降低68.5%和34.8% (P<0.01)。结论 钙化的血管组织中APN与其受体adipoR1系统是明显下调,APN可明显抑制钙化大鼠血管组织中钙含量和碱性磷酸酶的活性,提示APN可抑制维生素D3和尼古丁引起的血管钙化。
Abstract
Objective To observe the changes of adiponectin and its receptors in vascular calcification, and the role of adiponectin on calcified tissues. Methods Male SD rats were induced vascular calcification by vitamin D3 and nicotine, with or without adiponectin. Calcium and alkaline phosphatase (ALP) were assayed. The levels of APN in plasma and vascules were measured by ELISA. The mRNA levels of APN and adipo R1 were detected by using real-time PCR, the level of adipo R1 protein was detected by Western blotting. Results Compared with control group, the APN concentrations in plasma and calcified blood vessels decreased by 47.1% and 57.1%, respectively. The mRNA levels of APN and adipo R1 decreased by 65.0% and 72.0%.The adipo R1 protein decreased by 77.2%(P<0.01). 6.55 fold increase calcium and 83.4% increase in ALP activity were observed in calcified blood vessels than that in control group, while APN treatment down-regulated the calcium and ALP activity by 68.5% and 34.8% (P<0.01). Conclusions In calcified blood vessels, the APN and adipo R1 system are down-regulated, and APN decreases the calcium and ALP activity, suggesting that APN may have cardiovascular protection by antagonizing calcification.
关键词
血管钙化 /
脂联素 /
脂联素受体
Key words
vascular calcification /
adiponectin /
adipo R1
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Bostrom K. Insights into the mechanism of vascular calcification [J]. Am J Cardiol, 2001, 88 (2) : 20-22.
[2] 刘洪岩,谭洪勇,张金国. 脂联素在心血管疾病中的研究进展[J]. China Prac Med, 2009, 4(27): 229-232.
[3] 吴胜英, 张宝红, 蒋宏峰, 等. 血管钙化对血管组织内皮素表达的影响[J].中国动脉硬化杂志,2003, 11(4): 277-282.
[4] Liao Y, Takashima S, Maeda N, et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucosemetabolism[J]. Cardiovasc Res,2005, 67(4): 705-713.
[5] Antoniades C, Antonopoulos A S, Tousoulis D, et al. Adiponectin: from obesity to cardiovascular disease[J]. Obes Rev, 2009, 10(3): 269-279.
[6] 张宝红, 杜军保, 唐朝枢. 血管钙化的调节机制[J]. 心血管病学进展,2003, 24(3) : 179-181.
[7] Cai X J, Chen L, Li L, et al. Adiponectin inhibits lipopolysaccharide-induced adventitial fibroblast migration and transition to myofibroblasts via AdipoR1-AMPK-iNOS pathway [J]. Mol Endocrinol, 2010, 24(1): 218-228.
[8] Tomizawa A, Hattori Y, Kasai K. Induction of gene expression in response to globular adiponectin in vascular endothelial cells[J].Life Sci, 2009, 85(11-12): 457-461.
[9] Zoico E, Garbin U, Olioso D, et al. The effects of adiponectin on interleukin-6 and MCP-1 secretion in lipopolysaccharide-treated 3T3-L1 adipocytes: role of the NF-kappaB pathway [J]. Int JMol Med, 2009, 24(6): 847-851.
[10] Bostrom K, Watson K E, Horn S, et al. Bone morphogenetic protein expression in human atherosclerotic lesions[J]. J Clin Invest, 1993, 91(4):1800-1809.
[11] Chen Y J, Zhang L Q, Wang G P, et al. Adiponectin inhibits tissue factor expression and enhances tissue factor pathway inhibitor expression in hum an endothelial cells[J]. Thromb Haemost,2008,100(2): 291-300.
PDF(700 KB)
